Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 232,782,765 papers from all fields of science
Search
Sign In
Create Free Account
Stage IV Squamous Cell Lung Carcinoma
Known as:
Stage IV Squamous Cell Carcinoma of Lung
, Stage IV Squamous Cell Lung Carcinoma AJCC v7
, Metastatic Squamous Cell Carcinoma of Lung
Expand
Stage IV includes: (Any T, Any N, M1a); (Any T, Any N, M1b). M1a: Lung cancer with separate tumor nodule(s) in a contralateral lobe; tumor with…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
24 relations
Bronchial Epithelial Cell
Bronchial tree
Chest
Chromosome 13q deletion
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Clostridium perfringens empyema in a patient with metastatic squamous cell carcinoma of the lung
Daniel J Oh
,
S. Brecher
,
Marcus D. Ruopp
International Journal of Critical Illness and…
2018
Corpus ID: 49612262
We report a rare case of Clostridium perfringens (CP) empyema in a patient with metastatic squamous cell cancer of the lung…
Expand
2017
2017
Short-term efficacy and safety of apatinib in advanced squamous cell carcinoma of the lung.
Xiaowu Li
,
L. Le
,
Liang Han
,
Youwei Zhang
,
Sanyuan Sun
Indian Journal of Cancer
2017
Corpus ID: 44161794
OBJECTIVE To evaluate the short-term efficacy and safety of apatinib alone or combined with chemotherapy in the treatment of…
Expand
2015
2015
Alterations of a spectrum of driver genes in female Chinese patients with advanced or metastatic squamous cell carcinoma of the lung.
Z. Qiong
,
W. Na
,
+9 authors
Zheng Shu Seng
Lung Cancer
2015
Corpus ID: 37006234
Review
2014
Review
2014
Promising Targets and Current Clinical Trials in Metastatic Squamous Cell Lung Cancer
M. Vincent
Frontiers in Oncology
2014
Corpus ID: 15621798
Squamous cancer of the lung (SQCC), although no longer the premier variant of non-small cell lung cancer, continues to impose a…
Expand
2012
2012
Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/gefitinib (E/G) and chemotherapy: Interim subset analysis from a phase III trial.
J. Kim
,
F. Grossi
,
+8 authors
M. Schuler
2012
Corpus ID: 199042235
7558 Background: Patients with squamous NSCLC have limited treatment options. For those deriving benefit from EGFR TKIs, it is…
Expand
2006
2006
Erlotinib in patients with advanced squamous cell carcinoma of the lung.
A. Gúrpide
,
B. Massutí
,
+7 authors
L. Paz-Ares
Journal of Clinical Oncology
2006
Corpus ID: 10426811
7174 Background: Erlotinib is a potent HER1/EGFR TKI that is approved for the treatment as a single agent in 2nd and 3rd line…
Expand
Review
2005
Review
2005
Actinomyces meyeri isolation from synovial fluid of a patient with metastatic squamous cell lung carcinoma
H. M. Al-Attia
,
S. A. Kamel
2005
Corpus ID: 37816698
he coexistence of thyroid and parathyroid diseases is not rare. In the review of the recent literature, 25% of the patients with…
Expand
2005
2005
Actinomyces meyeri isolation from synovial fluid of a patient with metastatic squamous cell lung carcinoma.
E. Çetin
,
S. Kaya
,
M. Demirci
,
B. Aridogan
Saudi Medical Journal
2005
Corpus ID: 39633763
1999
1999
[Spinal and extra-spinal tumors mimicking discal herniation].
E. Tamir
,
Y. Mirovsky
,
D. Robinson
,
N. Halperin
Harefuah
1999
Corpus ID: 10735918
Low back pain radiating to a limb is usually caused by lumbar disc herniation. Tumors of the spinal cord or near the sciatic or…
Expand
1975
1975
Renal imaging in 99m-Tc-polyphosphate bone scanning: focal increased renal uptake in metastic carcinoma of lung.
P. M. Fitzer
Journal of Nuclear Medicine
1975
Corpus ID: 37103370
A small group of patients with normal intravenous urograms showed focal increased renal uptake, usually unilateral, of 99m-Tc…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE